These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 35702069)

  • 1. Immunological role and prognostic potential of CLEC10A in pan-cancer.
    Qin Y; Wang L; Zhang L; Li J; Liao L; Huang L; Li W; Yang J
    Am J Transl Res; 2022; 14(5):2844-2860. PubMed ID: 35702069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CLEC10A can serve as a potential therapeutic target and its level correlates with immune infiltration in breast cancer.
    Tang S; Zhang Y; Lin X; Wang H; Yong L; Zhang H; Cai F
    Oncol Lett; 2022 Aug; 24(2):285. PubMed ID: 35814828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High expression of CLEC10A in head and neck squamous cell carcinoma indicates favorable prognosis and high-level immune infiltration status.
    Zou M; Wu H; Zhou M; Xiao F; Abudushalamu G; Yao Y; Zhao F; Gao W; Yan X; Fan X; Wu G
    Cell Immunol; 2022 Feb; 372():104472. PubMed ID: 35093731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Significance and Immunological Role of FBXO5 in Human Cancers: A Systematic Pan-Cancer Analysis.
    Liu P; Wang X; Pan L; Han B; He Z
    Front Immunol; 2022; 13():901784. PubMed ID: 35720327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HHLA2 Used as a Potential Prognostic and Immunological Biomarker and Correlated with Tumor Microenvironment in Pan-Cancer.
    Yang Z; Xu D; Ye X; Lin X; Zhang M; Su Y; Xie Q; Ni W
    Biomed Res Int; 2022; 2022():3924400. PubMed ID: 35252444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insights Into the Prognostic Value and Immunological Role of NAAA in Pan-Cancer.
    Huang D; Shen J; Zhai L; Chen H; Fei J; Zhu X; Zhou J
    Front Immunol; 2021; 12():812713. PubMed ID: 35069601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
    Wang N; Zhu L; Wang L; Shen Z; Huang X
    Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. POC1A, prognostic biomarker of immunosuppressive microenvironment in cancer.
    Zhao Q; Gao S; Chen X; Zhu X
    Aging (Albany NY); 2022 Jun; 14(12):5195-5210. PubMed ID: 35748773
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Wu G; Chen M; Ren H; Sha X; He M; Ren K; Qi J; Lin F
    Front Cell Dev Biol; 2022; 10():930933. PubMed ID: 35874816
    [No Abstract]   [Full Text] [Related]  

  • 11. The Pan-Cancer Crosstalk Between the
    Xie R; Yuan M; Jiang Y
    Front Cell Dev Biol; 2022; 10():790947. PubMed ID: 35309935
    [No Abstract]   [Full Text] [Related]  

  • 12. An integrative analysis revealing POLD2 as a tumor suppressive immune protein and prognostic biomarker in pan-cancer.
    Cong F; Long J; Liu J; Deng Z; Yan B; Liang C; Huang X; Liu J; Tang W
    Front Genet; 2022; 13():877468. PubMed ID: 36081989
    [No Abstract]   [Full Text] [Related]  

  • 13. A comprehensive pan-cancer analysis on the immunological role and prognostic value of
    Yang Y; Jiang L; Wang S; Chen H; Yi M; Wu Y; Li Z; Fang X
    Transl Cancer Res; 2022 Sep; 11(9):3187-3208. PubMed ID: 36237259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FAIM2 is a potential pan-cancer biomarker for prognosis and immune infiltration.
    Cai J; Ye Z; Hu Y; Wang Y; Ye L; Gao L; Sun Q; Tong S; Sun Z; Yang J; Chen Q
    Front Oncol; 2022; 12():998336. PubMed ID: 36185230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. YTHDF1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy.
    Hu J; Qiu D; Yu A; Hu J; Deng H; Li H; Yi Z; Chen J; Zu X
    Front Oncol; 2021; 11():607224. PubMed ID: 34026603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Pan-Cancer Analysis of CD161, a Potential New Immune Checkpoint.
    Zhou X; Du J; Liu C; Zeng H; Chen Y; Liu L; Wu D
    Front Immunol; 2021; 12():688215. PubMed ID: 34305920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CLEC10A is a prognostic biomarker and correlated with clinical pathologic features and immune infiltrates in lung adenocarcinoma.
    He M; Han Y; Cai C; Liu P; Chen Y; Shen H; Xu X; Zeng S
    J Cell Mol Med; 2021 Apr; 25(7):3391-3399. PubMed ID: 33655701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic and immunological role of Ras-related protein Rap1b in pan-cancer.
    Cui G; Wang C; Lin Z; Feng X; Wei M; Miao Z; Sun Z; Wei F
    Bioengineered; 2021 Dec; 12(1):4828-4840. PubMed ID: 34346294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of
    Li J; Li X; Huang H; Tao L; Zhang C; Xie Y; Jiang Y
    J Oncol; 2022; 2022():9359879. PubMed ID: 36385955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The value of
    Feng Y; Wang Y; Guo K; Feng J; Shao C; Pan M; Ding P; Liu H; Duan H; Lu D; Wang Z; Zhang Y; Zhang Y; Han J; Li X; Yan X
    Ann Transl Med; 2022 Apr; 10(8):466. PubMed ID: 35571400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.